Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient
- Conditions
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 424
- Registration Number
- NCT03222843
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and technology, Wuhan, Hubei, China
🇨🇳West China Hospital，Sichuan University, Chengdu, Sichuan, China
🇨🇳Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT03185793
- Locations
- 🇨🇳
Jiangsu Hengrui Medicine Co., Ltd., Shanghai, Shanghai, China
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT03182673
- Locations
- 🇨🇳
The Cancer Center,Sun Yat-sen University, Guangzhou, Guangdong, China
Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03160014
- Locations
- 🇨🇳
XiJing Hospital, XiAn, Shanxi, China
Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03159832
- Locations
- 🇨🇳
Chinese people's liberation army general hospital of Chengdu military area, Chengdu, Sichuan, China
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT03159052
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT03155425
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 419
- Registration Number
- NCT03134872
- Locations
- 🇨🇳
Tongji University, Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT03131583
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT03121716
- Locations
- 🇨🇳
Jiangsu Hengrui, Shanghai, China